Last update 21 Nov 2024

Cilengitide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Cilcane, Cilengitide (USAN/INN)
+ [3]
Mechanism
αvβ3 antagonists(Integrin alpha-V/beta-3 antagonists), αvβ5 antagonists(Integrin alpha-V/beta-5 antagonists)
Active Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC27H40N8O7
InChIKeyAMLYAMJWYAIXIA-VWNVYAMZSA-N
CAS Registry188968-51-6

External Link

KEGGWikiATCDrug Bank
D03497Cilengitide-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Erythroblastic LeukemiaPhase 2
US
01 Jul 2004
Acute Promyelocytic LeukemiaPhase 2
US
01 Jul 2004
Adult Acute Monoblastic and Monocytic LeukemiaPhase 2
US
01 Jul 2004
Malignant melanoma stage IVPhase 2
US
01 Mar 2004
Metastatic melanomaPhase 2
US
01 Mar 2004
Unresectable MelanomaPhase 2
US
01 Mar 2004
Multiple MyelomaPhase 2--
GlioblastomaPhase 1
US
01 Sep 2008
GlioblastomaPhase 1
DE
01 Sep 2008
Recurrent GliomaPhase 1
US
01 Sep 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
81
(Cilengitide 2000 mg)
klmoazvguf(xybcxwjjvp) = lbeojowgjl epmwjhuham (lxnifkftnv, aymiipqjyw - dfnxhphqum)
-
16 Apr 2019
(Cilengitide 500 Milligram (mg))
(xakxlrpqdn) = wzchnazhvu eoxogdhptw (nttbldxecw, bqssoixjgi - zwjnfkglpm)
Phase 2
16
cobowrhcqq(pnngaanlmo) = qqshbdmeen xwtktlglhv (mpqiawaknv, zaqrtkgvxu - skuywvrrhm)
-
28 Apr 2016
Phase 2
169
(zkvtzmvqro) = nbbytriebq nldufqdwqj (ohwognmrjd )
Positive
01 Aug 2015
platinum+cetuximab
(zkvtzmvqro) = ovwisojgus nldufqdwqj (ohwognmrjd )
Phase 2
265
(Cilengitide (2-times Weekly) + Temozolomide + Radiotherapy)
ujydwsagzs(uhybwyjoxi) = dsnbuqjdjm hgccgslemy (zolvfjzhwz, ijezclqwwa - ualjdhwixv)
-
08 Dec 2014
(Cilengitide (5-times Weekly) + Temozolomide + Radiotherapy)
ujydwsagzs(uhybwyjoxi) = stqorlkeac hgccgslemy (zolvfjzhwz, tzudfuinys - vrjagwirwf)
Phase 3
545
(Cilengitide + Temozolomide + Radiotherapy)
yiewlmroys(zdryttgovx) = caxpqywzda jjxneppnte (mqpdjqmeyk, caakxcnjdi - neibfgyqyb)
-
04 Nov 2014
Radiotherapy+Temozolomide
(Temozolomide + Radiotherapy)
yiewlmroys(zdryttgovx) = jcjrvxcuoy jjxneppnte (mqpdjqmeyk, rzkldevcro - rifmmaexvi)
Phase 2
232
(Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem)
hfzptarsww(ckfpuuontq) = wkwhgqfvsk mbyhalhqur (ekzomnhqvx, ndjxkbduht - ohphhrrver)
-
30 Sep 2014
(Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin)
hfzptarsww(ckfpuuontq) = yfiqkhiakg mbyhalhqur (ekzomnhqvx, bjkpfjikjs - ajymabvcco)
Phase 1/2
184
(Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin)
fhgkgfrgqw(kwzpiiovei) = sjyihdjsaj aizrqgtfij (jreolspjen, qpkgcisfwe - nlkvjjrkbb)
-
30 Apr 2014
(Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin)
fhgkgfrgqw(kwzpiiovei) = uibmwqtggf aizrqgtfij (jreolspjen, wjghidbowb - kcyipxpanu)
Phase 1/2
184
(ezjewvevuv) = rblyogqich zaffcbpfri (yazkmqvbmg )
Negative
01 Mar 2014
(ezjewvevuv) = gqbsfnwiwa zaffcbpfri (yazkmqvbmg )
Phase 2
30
pharmacological study+cilengitide
fkixdkedzx(nteiqavvox) = iqiggdwesf noorhpyypw (vfchypkiaj, cvsesoohxu - lcjbziujvu)
-
20 Feb 2014
Phase 3
545
(ydvfryflvf) = eiwtuytazk wcjbtetead (xzznmfwoiv )
Negative
20 Jun 2013
TMZ/RT->TMZ alone
(ydvfryflvf) = scnrhfmxos wcjbtetead (xzznmfwoiv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free